U.S. flag

An official website of the United States government

NM_004260.4(RECQL4):c.1130A>G (p.Gln377Arg) AND not specified

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Mar 24, 2021
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001822008.4

Allele description [Variation Report for NM_004260.4(RECQL4):c.1130A>G (p.Gln377Arg)]

NM_004260.4(RECQL4):c.1130A>G (p.Gln377Arg)

Gene:
RECQL4:RecQ like helicase 4 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
8q24.3
Genomic location:
Preferred name:
NM_004260.4(RECQL4):c.1130A>G (p.Gln377Arg)
HGVS:
  • NC_000008.11:g.144515989T>C
  • NG_016430.2:g.6838A>G
  • NG_033083.1:g.3025T>C
  • NM_004260.4:c.1130A>GMANE SELECT
  • NP_004251.4:p.Gln377Arg
  • LRG_277t1:c.1130A>G
  • LRG_277:g.6838A>G
  • LRG_277p1:p.Gln377Arg
  • NC_000008.10:g.145741373T>C
  • NG_016430.1:g.6838A>G
  • NM_004260.3:c.1130A>G
Protein change:
Q377R
Links:
dbSNP: rs944826681
NCBI 1000 Genomes Browser:
rs944826681
Molecular consequence:
  • NM_004260.4:c.1130A>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:
AllHighlyPenetrant
Identifiers:
MedGen: CN169374

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002071415Genetic Services Laboratory, University of Chicago
criteria provided, single submitter

(ACMG Guidelines, 2015)
Uncertain significance
(Mar 24, 2021)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlinenonot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee..

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Details of each submission

From Genetic Services Laboratory, University of Chicago, SCV002071415.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

DNA sequence analysis of the RECQL4 gene demonstrated a sequence change, c.1130A>G, in exon 5 that results in an amino acid change, p.Gln377Arg. This sequence change has been described in gnomAD with a low frequency of 0.0056% (dbSNP rs944826681) in the East Asian sub-population. The p.Gln377Arg change affects a highly conserved amino acid residue located in a domain of the RECQL4 protein that is not known to be functional. The p.Gln377Arg substitution appears to be deleterious using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD). This sequence change does not appear to have been previously described in patients with RECQL4-related disorders. Due to the lack of sufficient evidences, the clinical significance of the p.Gln377Arg change remains unknown at this time.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenonot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024